Advisornet Financial’s Agile Therapeutics AGRX Stock Holding History

Advisornet Financial’s Portfolio AGRX Stock Details AGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-1	Closed	-$6K	–	1929
2020 Q2	$6K	Buy	+1	New	+$5.2K	﹤0.01%	1428

Other funds holding AGRX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

DCM

DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FMBTD

First Midwest Bank Trust Division Joliet, Illinois $777M AUM 29.48% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Advisornet Financial's AGRX Position: Q3 2020 in Review

Advisornet Financial sold out of Agile Therapeutics (AGRX) in Q3 2020, closing a stake of 1 share — an estimated $6K sold.

Advisornet Financial first reported a position in AGRX in Q2 2020 and held it in 1 quarter. The position peaked at $6K in Q2 2020. 75 funds tracked by Wall St. Rank hold AGRX as of Q3 2020.

Advisornet Financial reported no remaining Agile Therapeutics position as of Q3 2020 after selling out during the quarter.
Advisornet Financial sold 1 Agile Therapeutics share in Q3 2020, an estimated $6K.
Advisornet Financial first reported a position in Agile Therapeutics in Q2 2020 and held it in 1 quarter.
Advisornet Financial's Agile Therapeutics position peaked at $6K in Q2 2020.
75 funds tracked by Wall St. Rank held Agile Therapeutics as of Q3 2020.

Based on Advisornet Financial's 13F filing for Q3 2020, filed 6 Nov 2020.